Candriam SCA’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $122M | Buy |
195,674
+9,286
| +5% | +$6.32M | 0.55% | 36 |
|
|
2026
Q1 | $144M | Sell |
186,388
-18,944
| -9% | -$14.5M | 0.75% | 24 |
|
|
2025
Q4 | $158M | Buy |
205,332
+35,837
| +21% | +$24.3M | 0.79% | 22 |
|
|
2025
Q3 | $95.3M | Buy |
169,495
+27,287
| +19% | +$15.4M | 0.5% | 38 |
|
|
2025
Q2 | $74.7M | Sell |
142,208
-72,733
| -34% | -$40.6M | 0.43% | 51 |
|
|
2025
Q1 | $136M | Sell |
214,941
-46,557
| -18% | -$32M | 0.85% | 24 |
|
|
2024
Q4 | $186M | Buy |
261,498
+8,973
| +4% | +$7.53M | 1.07% | 16 |
|
|
2024
Q3 | $265M | Buy |
252,525
+51,817
| +26% | +$57.7M | 1.53% | 9 |
|
|
2024
Q2 | $211M | Sell |
200,708
-17,063
| -8% | -$16.5M | 1.28% | 11 |
|
|
2024
Q1 | $210M | Sell |
217,771
-23,847
| -10% | -$22.7M | 1.34% | 10 |
|
|
2023
Q4 | $212M | Sell |
241,618
-48,692
| -17% | -$40.1M | 1.46% | 10 |
|
|
2023
Q3 | $239M | Sell |
290,310
-15,308
| -5% | -$12M | 1.69% | 9 |
|
|
2023
Q2 | $220M | Sell |
305,618
-43,370
| -12% | -$33.4M | 1.59% | 7 |
|
|
2023
Q1 | $264M | Sell |
348,988
-33,980
| -9% | -$25.6M | 1.83% | 5 |
|
|
2022
Q4 | $276M | Sell |
382,968
-19,553
| -5% | -$14.4M | 1.86% | 5 |
|
|
2022
Q3 | $277M | Buy |
402,521
+29,728
| +8% | +$18.7M | 1.95% | 5 |
|
|
2022
Q2 | $220M | Buy |
372,793
+3,503
| +0.9% | +$2.28M | 1.81% | 7 |
|
|
2022
Q1 | $258M | Buy |
369,290
+4,704
| +1% | +$2.98M | 1.76% | 5 |
|
|
2021
Q4 | $230M | Sell |
364,586
-24,057
| -6% | -$14.8M | 1.47% | 7 |
|
|
2021
Q3 | $235M | Sell |
388,643
-141,703
| -27% | -$88M | 1.6% | 7 |
|
|
2021
Q2 | $296M | Buy |
530,346
+126,705
| +31% | +$64.2M | 2.03% | 5 |
|
|
2021
Q1 | $187M | Buy |
403,641
+4
| +0% | +$1.95K | 1.56% | 6 |
|
|
2020
Q4 | $195M | Buy |
403,637
+80,601
| +25% | +$43.5M | 1.54% | 6 |
|
|
2020
Q3 | $181M | Buy |
323,036
+94,135
| +41% | +$57.1M | 1.7% | 7 |
|
|
2020
Q2 | $143M | Sell |
228,901
-182,315
| -44% | -$103M | 1.51% | 8 |
|
|
2020
Q1 | $151M | Buy |
411,216
+5
| +0% | +$2.06K | 1.67% | 8 |
|
|
2019
Q4 | $154M | Sell |
411,211
-963
| -0.2% | -$324K | 1.65% | 8 |
|
|
2019
Q3 | $114M | Buy |
412,174
+26,433
| +7% | +$7.82M | 1.52% | 11 |
|
|
2019
Q2 | $120M | Buy |
385,741
+38,470
| +11% | +$12.8M | 1.5% | 12 |
|
|
2019
Q1 | $143M | Sell |
347,271
-2,083
| -0.6% | -$858K | 1.82% | 5 |
|
|
2018
Q4 | $130M | Buy |
349,354
+2,971
| +0.9% | +$1.09M | 2.01% | 5 |
|
|
2018
Q3 | $140M | Buy |
346,383
+157,800
| +84% | +$60.1M | 1.86% | 6 |
|
|
2018
Q2 | $65.1M | Buy |
188,583
+58,963
| +45% | +$18.4M | 1.03% | 11 |
|
|
2018
Q1 | $44.6M | Buy |
129,620
+8,528
| +7% | +$2.97M | 0.76% | 18 |
|
|
2017
Q4 | $45.5M | Sell |
121,092
-9,900
| -8% | -$4.01M | 0.79% | 16 |
|
|
2017
Q3 | $58.6M | Buy |
130,992
+3,449
| +3% | +$1.64M | 1.02% | 13 |
|
|
2017
Q2 | $62.6M | Sell |
127,543
-43,180
| -25% | -$18.9M | 1.18% | 11 |
|
|
2017
Q1 | $66.2M | Buy |
170,723
+62,878
| +58% | +$23.3M | 1.28% | 10 |
|
|
2016
Q4 | $39.6M | Buy |
107,845
+1,635
| +2% | +$622K | 0.91% | 16 |
|
|
2016
Q3 | $42.7M | Buy |
106,210
+11,106
| +12% | +$4.46M | 1.03% | 13 |
|
|
2016
Q2 | $33.2M | Buy |
95,104
+24,146
| +34% | +$9.3M | 0.86% | 20 |
|
|
2016
Q1 | $25.4M | Sell |
70,958
-25,965
| -27% | -$10.7M | 0.64% | 33 |
|
|
2015
Q4 | $52.6M | Sell |
96,923
-10,945
| -10% | -$5.93M | 1.41% | 9 |
|
|
2015
Q3 | $50.2M | Sell |
107,868
-14,485
| -12% | -$7.78M | 1.23% | 9 |
|
|
2015
Q2 | $62.4M | Buy |
122,353
+3,100
| +3% | +$1.51M | 1.3% | 8 |
|
|
2015
Q1 | $53.9M | Buy |
119,253
+39,112
| +49% | +$16.6M | 1.08% | 10 |
|
|
2014
Q4 | $32.9M | Buy |
+80,141
| New | +$31.5M | 0.69% | 32 |
|
Other funds holding REGN
Candriam SCA's REGN Position: Q2 2026 in Review
Candriam SCA increased its Regeneron Pharmaceuticals (REGN) stake by 5% in Q2 2026, buying an estimated $6.32M and bringing the position to 195,674 shares worth $122M. The position accounts for 0.55% of the portfolio, ranked #36.
Candriam SCA first reported a position in REGN in Q4 2014 and has held it in 47 quarters since. The position peaked at $296M in Q2 2021. 1,330 funds tracked by Wall St. Rank hold REGN as of Q2 2026.
- Candriam SCA held 195,674 shares of Regeneron Pharmaceuticals worth $122M as of Q2 2026.
- Candriam SCA bought 9,286 Regeneron Pharmaceuticals shares in Q2 2026, an estimated $6.32M.
- Regeneron Pharmaceuticals made up 0.55% of Candriam SCA's portfolio in Q2 2026, its #36 holding.
- Candriam SCA first reported a position in Regeneron Pharmaceuticals in Q4 2014 and has held it in 47 quarters since.
- Candriam SCA's Regeneron Pharmaceuticals position peaked at $296M in Q2 2021.
- 1,330 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q2 2026.
Based on Candriam SCA's 13F filing for Q2 2026, filed 13 Aug 2026.